贝伐单抗与顺铂联合治疗非小细胞肺癌恶性胸腔积液的疗效观察

Efficacy of Bevacizumab Combined with Cisplatin in the Treatment of Malignant Pleural Effusion in Non-small Cell Lung Cancer

目的探讨贝伐单抗与顺铂联合治疗非小细胞肺癌恶性胸腔积液的疗效。方法研究对象均为2016年1月至2019年1月我院收治的非小细胞肺癌伴恶性胸腔积液患者,共计72例。将其以随机数表法进行组别划分,其中对照组与研究组各纳入患者36例。对照组采用单纯顺铂治疗,研究组采用贝伐单抗与顺铂联合治疗。通过实体瘤疗效评价标准(RESIST)评价两组临床疗效,并记录治疗期间的不良反应。结果两组患者治疗的总有效率比较中,研究组61.11%较对照组30.56%更高(P<0.05)。两组治疗期间恶心呕吐、白细胞减少、肝肾功能异常、心率失常与皮疹的发生率对比无明显差异(P>0.05)。结论非小细胞肺癌恶性胸腔积液患者采用贝伐单抗与顺铂联合治疗能够取得满意的临床疗效,值得临床推广。

Objective To investigate the efficacy of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion in non-small cell lung cancer.Methods Seventy-two cases of non-small cell lung cancer with malignant pleural effusion were selected from January 2016 to January 2019.Random number table method was used to divide 36 cases into control group and research group.The control group was treated with cisplatin alone,while the study group was treated with bevacizumab combined with cisplatin.Result The total effective rate of the two groups was 61.11%in the study group and 30.56%in the control group(P<0.05).There was no significant difference in the incidence of nausea and vomiting,leukopenia,abnormal liver and kidney function,arrhythmia and rash between the two groups(P>0.05).Conclusion Bevacizumab combined with cisplatin in the treatment of malignant pleural effusion in patients with non-small cell lung cancer can achieve satisfactory clinical efficacy,which is worthy of clinical promotion.